<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146268">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01868386</url>
  </required_header>
  <id_info>
    <org_study_id>16604</org_study_id>
    <nct_id>NCT01868386</nct_id>
  </id_info>
  <brief_title>Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate</brief_title>
  <official_title>Hypofractionated Post-prostatectomy Radiotherapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Showalter, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation therapy is one of the standard treatments for men with prostate cancer who have
      detectable levels of prostate specific antigen (PSA, a prostate cancer specific marker)
      after surgery. When radiation therapy is given to patients who have an increase in PSA after
      surgery, it is called &quot;salvage radiation therapy&quot;.  Currently the standard radiation therapy
      course length for this type of cancer is around 7 Â½ -8 weeks. Sometimes, radiation therapy
      after prostate removal causes unpleasant side effects.  A shorter course of radiation
      therapy, known as a &quot;hypofractionated&quot; course, gives fewer but higher doses of radiation
      than standard radiation.

      The purpose of this study is to test the safety of a shorter course of radiation therapy at
      progressively lower dose levels and shorter lengths of treatment (hypofractionated) with
      patients who have had their prostate removed.  The study will assess whether the
      hypofractionated course works better without causing additional side effects to the
      remaining cancer cells in the prostate bed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>over a period of 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of GU (genitourinary) and GI (gastrointestinal) toxicities of CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or greater</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life measure</measure>
    <time_frame>over a period of 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare quality of life post-procedure from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure rate</measure>
    <time_frame>over a period of 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>A biochemical failure is defined as an increase in prostate serum antigen concentration to nadir plus 2ng/mL or 3 consecutive increases in PSA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute and late GU and GI toxicity</measure>
    <time_frame>over a period of two years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Health Utilities</measure>
    <time_frame>1 year after radiation treatment</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>EPIC Prostate Cancer-Specific QOL instrument</measure>
    <time_frame>over a period of two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>looking at changes in sexual and hormonal domains</description>
  </other_outcome>
  <other_outcome>
    <measure>Ancillary financial burden</measure>
    <time_frame>over a period of two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>estimating out-of-pocket costs and lost wages for patients during treatment</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated therapy, 26 treatments at 2.5 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated therapy, 20 treatments at 2.83Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated therapy,15 treatments at 3.36 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated therapy, 10 treatments at 4.26 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated therapy</intervention_name>
    <description>Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of prostate adenocarcinoma and

          -  have had a prostatectomy

          -  have detectable PSA

          -  18 years of age or older

        Exclusion Criteria:

          -  are receiving chemotherapy or other agents intended for cancer treatment

          -  history of rectal surgery or lower gastrointestinal bleed

          -  history of bleeding diathesis or abnormal sensitivity to ionizing radiation

          -  had prior pelvic irradiation or  are scheduled to receive pelvic nodal irradiation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Showalter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy K Camblos</last_name>
    <phone>434-243-1927</phone>
    <email>uvahypofx@virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Showalter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Timothy Showalter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Larner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Culp, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tracey Krupski, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marguerite Lippert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Read, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noah Schenkman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Steers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Timothy Showalter, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy, hypofractionated</keyword>
  <keyword>Salvage therapy</keyword>
  <keyword>Radiotherapy, adjuvant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
